As of March 22, 2024, Mark L. mark baum net worth is at least $37.5 million. He owns over 9,000 units of Harrow Health stock, valued at approximately $35,889,045. Over the past decade, he has sold HROW stock worth over $219,135. Additionally, his annual earnings as Chief Executive Officer and Director at Harrow Health amount to $1,377,010.
Early Life
mark baum net worth journey to becoming a successful CEO and entrepreneur began with a strong educational foundation. He graduated cum laude from The University of Texas at Arlington and later earned his law degree from California Western School of Law. His early career was marked by diverse experiences in law and business, setting the stage for his future success.
Before joining Harrow Health, Baum founded and served as president of Year, a company that focused on providing innovative pharmacy services. His expertise as a U.S. securities lawyer, specializing in public company reporting requirements and finance-related matters, further solidified his reputation in the industry.
Baum’s entrepreneurial spirit led him to establish TBLF, LLC, a consulting firm and fund manager, where he managed three funds and acted as a principal investor in financing publicly traded companies. These early ventures laid the groundwork for his future leadership roles and success in the pharmaceutical industry
Mark Baum Stock Trading Activity
According to SEC Form 4, Mark Baum has made more than 16 trades involving Harrow Health stock since 2015. His most recent purchase was on March 22, 2024, when he acquired 9,000 units of HROW stock for $104,310. The largest trade he made was on April 25, 2021, when he exercised 850,000 units of Harrow Health stock valued at over $14,271,500. On average, he trades approximately 85,147 units every 95 days. As of March 22, 2024, Baum owns at least 2,137,525 units of Harrow Health stock.
Mark Baum Biography
Mark L. Baum, J.D., serves as the Chief Executive Officer and Director of Harrow Health. In 2011, he led the restructuring and reorganization of the company and has since guided its unique business model’s development and growth. Baum joined Harrow Health as a director in December 2011, became Chairman of the Board of Directors from December 2011 to April 2012, and was appointed CEO in April 2012.
Before his tenure at Harrow Health, from 2001 to 2011, Baum was the founder and managing director of TBLF, LLC, a consulting firm and fund manager. He managed three funds and acted as a principal investor in financing publicly traded companies. Baum also founded and served as president of Year and practiced as a U.S. securities lawyer, focusing on public company reporting requirements and finance-related matters.
Baum is also a founder and board member of Eton Pharmaceuticals, Inc., Surface Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and Harrow Health’s subsidiaries, Mayfield Pharmaceuticals, Inc., and Bradley Pharmaceuticals, Inc. He served on Ideal Power, Inc.’s board of directors from November 2012 to December 2017, chairing its audit committee. Baum holds a cum laude degree from The University of Texas at Arlington and is a graduate of California Western School of Law.
Mark Baum Compensation
As CEO and Director of Harrow Health, Baum receives a total compensation of $1,377,010 annually. No other executive at Harrow Health earns a higher salary.
Age and Background
Mark Baum is 47 years old and has served as CEO and Director of Harrow Health since 2012. Among the company’s executives, nine are older, and two are younger. The oldest executive is Dr. Robert J. Kammer, D.D.S., who is 72 years old and serves as a Special Advisor.
Mailing Address
Mark Baum mailing address is C/O HARROW, INC., 102 WOODMONT BLVD, SUITE 610, NASHVILLE, TN, 37205.
Insider Trading at Harrow Health
In the past five years, insiders at Harrow Health have traded over $1,363,111 worth of company stock and purchased 1,487,560 units worth $12,882,479. The most active traders include Opal eye Management Inc., Mark L. Baum, and Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days, with each trade averaging $1,349,009. The most recent stock trade was by Opaleye Management Inc. on April 25, 2024, involving 20,000 units of HROW stock worth $199,400.
Harrow Health Overview
Harrow Health, Inc. is an ophthalmic-focused healthcare company. It owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business, and DEXYCU for post-operative inflammation treatment. The company holds equity interests in Surface Ophthalmic, Inc., Melt Pharmaceuticals, Inc., and Eton Pharmaceuticals, Inc. Harrow Health also owns royalty rights in four clinical-stage drug candidates developed by Surface Ophthalmic, Inc. and Melt Pharmaceuticals, Inc. Founded in 2006 and headquartered in San Diego, California, the company was formerly known as Imprecise Pharmaceuticals, Inc., before changing its name to Harrow Health, Inc. in December 2018.
Mark Baum Net Worth Summary
As of March 22, 2024, mark baum net worth is estimated to be at least $37.5 million. He owns over 9,000 units of Harrow Health stock, valued at approximately $35,889,045. Over the past decade, he has sold Harrow Health stock worth over $219,135. Additionally, he earns an annual salary of $1,377,010 as the Chief Executive Officer and Director of Harrow Health. Baum’s substantial net worth reflects his successful career and strategic investments in the pharmaceutical industry. Please visit https://newviralblog.com/
FAQs about Mark Baum Net Worth
What is Mark Baum estimated net worth?
As of March 22, 2024, Mark L. Baum’s net worth is estimated to be at least $37.5 million.
How much Harrow Health stock does Mark Baum own?
Mark Baum owns over 9,000 units of Harrow Health stock, valued at approximately $35,889,045.
How much has Mark Baum earned from selling Harrow Health stock?
Over the past decade, Mark Baum has sold Harrow Health stock worth over $219,135.
What is Mark Baum annual salary at Harrow Health?
Mark Baum earns an annual salary of $1,377,010 as the Chief Executive Officer and Director of Harrow Health.
How many trades has Mark Baum made with Harrow Health stock?
Since 2015, Mark Baum has made over 16 trades involving Harrow Health stock.
What was Mark Baum largest trade with Harrow Health stock?
The largest trade Mark Baum made was exercising 850,000 units of Harrow Health stock on April 25, 2021, worth over $14,271,500.
What other companies is Mark Baum involved with?
Mark Baum is a founder and board member of Eton Pharmaceuticals, Inc., Surface Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., and Harrow Health’s subsidiaries Mayfield Pharmaceuticals, Inc., and Radley Pharmaceuticals, Inc.
What is Mark Baum educational background?
Mark Baum graduated cum laude from The University of Texas at Arlington and earned his law degree from California Western School of Law.
What roles has Mark Baum held at Harrow Health?
Mark Baum has been a director of Harrow Health since December 2011, served as Chairman of the Board from December 2011 to April 2012, and has been the Chief Executive Officer since April 2012.
Where is Mark Baum mailing address?
Mark Baum mailing address is C/O HARROW, INC., 102 WOODMONT BLVD, SUITE 610, NASHVILLE, TN, 37205
